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Abstract 15 
Background 16 
The diagnosis of canine soft tissue sarcoma (STS) is based on histological assessment. 17 
Assessment of criteria such as, degree of differentiation, necrosis score and mitotic score, 18 
gives rise to a final tumour grade, which is important in the recommendation of treatment 19 
and prognosis of patients. 20 
Materials and Methods 21 
Previously diagnosed cases of STS were independently assessed by three board-certified 22 
veterinary pathologists. Participating pathologists were blinded to the original results. For the 23 
intra-observer study, the cases were assessed by a single pathologist six months apart and 24 
slides were randomized between readings. For the inter-observer study, the whole case 25 
series was assessed by a single pathologist before being passed onto the next pathologist. 26 
Intraclass correlation coefficient (ICC) and Fleiss's Kappa (ƙ) for the intra- (single observer) 27 
and inter-observer agreement. 28 
Results 29 
Strong agreement was observed for the intra-observer assessment in necrosis score, mitotic 30 
score, total score and tumour grading (ICC between 0.78 to 0.91). The intra-observer 31 
agreement for differentiation score was rated perfect (ICC 1.00). The agreement between 32 
pathologists for the diagnosis and grading of canine STS was moderate (ƙ = 0.60 and 0.43 33 
respectively). 34 
Conclusion 35 
Histological assessment of canine STS had high reproducibility by an individual pathologist. 36 
The agreement of diagnosis and grading of canine STS was moderate between pathologists. 37 
Future studies are required to investigate further assessment criteria to improve the 38 
specificity of STS diagnosis and the accuracy of the STS grading in dogs.  39 
Introduction 40 
Soft tissue sarcoma (STS) includes a heterogeneous group of mesenchymal neoplasms 41 
derived from soft tissues.1 It is reported to represent 15% of all skin and subcutaneous 42 
tumours in dogs and 7% in cats.2 STSs are typically considered locally invasive and 43 
potentially metastatic tumours. However, rates of local recurrence and metastasis are 44 
variable, making accurate prognostication in individual cases difficult.1 45 
Various tumour subtypes such as fibrosarcoma, myxosarcoma, liposarcoma, perivascular 46 
wall tumour, and peripheral nerve sheath tumour are included in the STS group.1 A few 47 
studies have described a trend that suggest fibrosarcoma and liposarcoma may carry a 48 
worse prognosis than other STS subtypes.3-5 However, the histological subtype currently has 49 
little bearing on the clinical management of these tumours as more studies are needed to 50 
confirm and measure differences in prognosis among sufficient numbers of tumours of each 51 
subtype.1 In addition, an accurate identification of the STS subtype frequently relies on a 52 
large panel of immunohistochemical markers, including those applied to frozen sections1, 53 
making this practice difficult to be routinely applied in the clinical setting.  54 
Genetic alterations have been showed in STS in human and dogs.6,7 The advances in this 55 
field have improved diagnostic accuracy in human STS.6 These alterations included 56 
chromosomal translocation, chromosomal numerical changes, oncogenic mutations, gene 57 
amplifications or deletions.6-7 Veterinary research in the genetic alterations in STS is vastly 58 
limited; however, future research in this field may provide objective diagnosis, improve 59 
prognostication as well as the development of possible targeted gene therapy. 60 
Presently the most used histological parameter to prognosticate STSs in dogs is the tumour 61 
grade, which is calculated based on cellular differentiation, mitotic rate and percentage of 62 
tumour necrosis. The application of these histologic criteria allows individual STSs to be 63 
categorized into three grades (I-low grade, II-intermediate grade or III-high grade).3,8-11 64 
Previous studies have indicated that the grade is strongly predictive for local recurrence in 65 
marginally excised canine STSs.11 66 
Multivariable analysis indicated that mitotic rate and percentage of tumour necrosis are the 67 
only statistically significant prognostic elements of the grading scheme.3 The mitotic rate is 68 
predictive for distant metastasis,3 survival time,1,3,4 and local recurrence.4 Tumour necrosis, 69 
is prognostic for survival time after surgery.3 To date, no single histological criterion has 70 
been shown to be a consistent prognostic factor in local recurrence and other patient 71 
outcome assessments (such as distant metastasis, survival time and disease free interval) 72 
amongst studies. Histologically incomplete margin was significantly associated with 73 
decreased disease-free intervals and survival times.12 There was also a trend of shorter 74 
survival time and higher local recurrence with larger tumour size; however, a statistical 75 
significance was not found.4-12 76 
Comparatively, histological grading is the most important prognostic factor for STS in human 77 
patients.9 Despite this, grade discrepancies are reported in 25 – 34.6% human adult STS 78 
cases.8,10 In addition, the agreement for the diagnosis of non-visceral STS in humans was 79 
reported to be 78% between pathologists.  80 
The objective of this study was to assess intra- and inter-observer agreement of histological 81 
assessment of canine STS; included criteria were tumour differentiation, mitotic rate, 82 
percentage of tumour necrosis, final diagnosis of STS and overall tumour grade.  83 
Materials and methods 84 
Samples 85 
Haematoxylin and eosin stained histology slides of tissue samples previously diagnosed as 86 
canine STS were collected from two veterinary referral hospitals. Soft tissue sarcomas 87 
excised for curative intent, for cytoreductive intent or for excisional biopsies were included. 88 
Oral and visceral STS as well as mesenchymal tumours such as synovial cell sarcoma, 89 
osteosarcoma, haemangiosarcoma and round cell tumour were excluded. 90 
The laboratory identification codes on the histology slide were covered for anonymization 91 
and all the cases were numbered sequentially. 92 
Grading and scoring of the tissue sections 93 
Previously diagnosed cases of STS were independently assessed by three board-certified 94 
veterinary pathologists. Participating pathologists were blinded to the original results, e.g. 95 
tumour subtype and grade, and each other’s conclusions. In order to minimise inconsistency 96 
among pathologists, previous recommendations on the assessment of STS were adopted.1 97 
These recommendations included assessment of areas that were well-fixed and not overly 98 
complicated by inflammation and/or haemorrhage; mitotic index was assessed within the 99 
most cellular part of the tumour and the area with the highest mitotic activity; differentiation 100 
represented the histologic type and true differentiation of the tumour but that uncertainty 101 
regarding histogenesis had no bearing on degree of differentiation.1  102 
For the intra-observer study, the cases were assessed by a single pathologist six months 103 
apart and slides were randomized between readings. For the inter-observer study, the whole 104 
case series was assessed by a single pathologist before being passed onto the next 105 
pathologist. 106 
Initial evaluation targeted confirmation of the original diagnosis of STS. Cases where there 107 
was disagreement on the diagnosis of STS were excluded for the subsequent assessment of  108 
each canine STS histological parameter.1 Criteria encompassed tumour differentiation, 109 
mitotic rate and percentage of tumour necrosis.1 In concordance with the grading system, a 110 
correlating score was assigned for each criterion (Table 1).1 A final tumour grade was 111 
assigned based on the cumulative score from these three criteria (Table 2).1 The histologic 112 
subtype of the tumour was not assessed.  113 
Statistical analyses were performed using a web-based program (StatsToDo at 114 
www.statstodo.com). Intraclass correlation coefficient (ICC) and Fleiss’s Kappa (κ) for the 115 
numerical and categorical values were calculated for the intra- (single observer) and inter-116 
observer agreement (three observers). Interpretation of the ICC and the κ values is indicated 117 
in Table 3.  118 
Results 119 
Intra-observer study 120 
Of 77 cases assessed by the pathologist 7 were considered to not be a STS. Of the cases 121 
that were considered STS, tumour grading between the two readings differed in 6/70 cases 122 
(8.6%). Of these 6 cases 2 had a different mitotic score and 4 cases had different necrosis 123 
scores, resulting in different final tumour grading. One case had a mitotic score difference of 124 
‘1’ and the other case had a difference of ‘2’ between assessment, based on previously 125 
established assessment score.1 The other four cases had a difference in necrosis score of 126 
‘1’.1 All these six cases had the same differentiation score for both assessments. 127 
Strong agreement was observed for the intra-observer assessment in necrosis score, mitotic 128 
score, total score and tumour grading (ICC between 0.78 to 0.91) (Table 4). The intra-129 
observer agreement for differentiation score was rated perfect (ICC = 1.00).  130 
Inter-observer study 131 
Of the 77 samples previously diagnosed as STS 3 were unanimously assessed as non-STS 132 
by all the pathologists. The presumptive diagnosis for these cases included histiocytic 133 
sarcoma, haemangiosarcoma, round cell tumour, osteosarcoma, and amelanotic melanoma. 134 
Of the 77 cases, disagreement of the diagnosis of STS (is it a STS?) was present in 8 cases 135 
(10.4%) (Figure 1) (ie, the agreement between pathologists for the diagnosis of STS was 136 
89.6%). The presumptive diagnosis of these cases included chondrosarcoma, 137 
osteosarcoma, histiocytic sarcoma, amelanotic melanoma, haemangiosarcoma, suture 138 
material reaction and granulation tissue. Five of these cases had disagreement between 139 
STS and another malignant tumour; 3 of these cases had disagreement between STS and a 140 
benign process (suture material reaction or granulation tissue). The 3 cases unanimously 141 
assessed to be a non-STS and the 8 disagreed cases were excluded for the subsequent 142 
part of the study (assessment of the histological criteria). 143 
For 35/66 (53%) of the cases, at least 1 pathologist disagreed with the tumour grading. The 144 
disagreement was only between adjacent grades (i.e. between grade I and II, and between 145 
grade II and III); there was no disagreement between tumour grade I and III. . Most cases of 146 
disagreement (27/35) were between grade I and grade II.  147 
The agreement for the diagnosis of STS, mitotic scores, necrosis scores and tumour grades 148 
were moderate among observers (κ between 0.43 to 0.60) (Table 5). The differentiation 149 
score had poor agreement (κ = 0.11) and the total score for all histological criteria had poor 150 
agreement (κ = 0.20) among observers (Table 5). If differentiation score was removed from 151 
the calculation of the total score, the inter-observer agreement improved to κ value of 0.44; 152 
this was an improvement of total score from fair to moderate agreement.  153 
Discussion 154 
Histological assessment remains the main tool for the diagnosis canine STS. As a result, 155 
discrepancies of the diagnosis as well as grading of STS can have a profound effect on case 156 
management and prognosis. Agreement in the diagnosis of STS in our study was 89.6% 157 
between pathologists, compared favourably to that reported in human non-visceral soft 158 
tissue sarcomas (78%).13 In general, misdiagnosis of tumours may lead to increased patient 159 
morbidity or mortality through inappropriately tailored treatment, either the absence or 160 
administration of unnecessary treatment, such as aggressive surgical excision with or 161 
without follow-up radiotherapy in a benign lesion. Misdiagnosis of other tumours as STS may 162 
also affect prognostication of patients (eg, haemangiosarcoma vs STS). 163 
Tumour grading has been regarded as the most important prognostic factor and best 164 
indicator of metastatic risk in human adult STS.9 In veterinary medicine, STS tumour grading 165 
has been shown to be a predictive factor for local recurrence.11, 14 The agreement on STS 166 
histological grading in this study was moderate (κ = 0.44), which was similar to that in human 167 
medicine (κ = 0.49).8 Histological grading of STS can influence the recommendation of 168 
surgical margins, with margins of <1 – 3 cm being described as acceptable for low grade 169 
STS.15,16 In comparison, other authors advised at least 3 cm peripheral margins and a deep 170 
margin of fascial plane for STS excision.17 Tumour grading can also affect recommendations 171 
on further treatment for marginally excised STS; some authors supported a more 172 
conservative approach for marginally excised grade I and II STS.11 If conservative approach 173 
is adopted for a marginally excised high grade STS misdiagnosed as a lower grade tumour, 174 
local recurrence is likely. Local recurrence has been shown to be associated with tumour-175 
related death.14 On the other hand, an animal with low grade STS misdiagnosed as high 176 
grade STS may receive unnecessary adjunctive treatment, such as aggressive scar excision 177 
or adjunctive radiotherapy. At the author’s institution, tumour excision is recommended for 178 
grade III tumours, followed by adjunctive therapy. In contrast, grade I tumours (and often 179 
grade II) are excised with margins and are monitored without further adjunctive treatment. 180 
Tumour grade of STS may also play a role in metastasis. In some studies, grade III STS has 181 
been shown to be significantly associated with metastasis (regional and distant).3,18 In these 182 
studies, metastasis was reported to be as high as 44% of the grade III cases. 3,18 This further 183 
emphasised the importance of consistent and accurate tumour grading, especially for 184 
prognostication of an individual patient. 185 
Inconsistency in histological diagnosis and grading of canine STS also has a bearing on 186 
interpretation of published and future literature. Currently, majority of the literature on canine 187 
STS investigated patient outcome based on retrospective information histological diagnosis 188 
of STS and the grading. Clearly, inconsistency in these histological assessments may raise 189 
question over the results produced by these studies. In addition, the inconsistency might 190 
also play a role in the variable results between studies, explaining why histological criteria, 191 
such as mitotic rate and degree of tumour necrosis, have been shown to be prognostic 192 
factors for various patient outcome assessment in some studies, but not in others.1,3,11 Other 193 
factors that may result in variation in results between studies include different sample sizes, 194 
different methodology in case selection and patient outcome assessment. 195 
In the intra-observer study, final tumour grading differed in 6 cases. In these cases, 196 
differences in mitotic and necrosis scores between the assessments resulted in final tumour 197 
grade disagreement. Interestingly, the differentiation score was consistent throughout these 198 
six cases, despite it being the most subjective criterion of the 3 in the inter-observer study 199 
(poor agreement). The marked difference in agreement of the differentiation score for intra-200 
observer (perfect) and inter-observer (poor) could reflect the subjectivity in individual’s 201 
interpretation of ‘degree of resemblance of sarcoma tissue to normal adult mesenchymal 202 
tissue’.  203 
Mitotic score and degree of necrosis have been established to be prognostic indicators for 204 
survival time, distant metastasis and local recurrence.3,4 These 2 criteria are more objective 205 
in comparison to the tumour differentiation. Despite the objectivity of these criteria, the 206 
agreement between observers was only moderate, in contrast to the strong intra-observer 207 
agreement.  This could be due to variability in microscope field selection for the assessment 208 
as well as subjectivity in estimating the percentage of necrosis. In addition, the actual size of 209 
the field assessed for the mitotic scoring could vary based on different microscopes.19 The 210 
variability in these criteria result in variability in the total cumulative score and resultant 211 
tumour grading. Unfortunately, this variability represents the ‘real-life’ situation in clinical 212 
setting as histological slides are assessed by different pathologists, at different laboratories 213 
and using different microscopes. 214 
Agreement on tumour differentiation was poor among observers. This was likely to be 215 
secondary to the subjective nature of this assessment. However, microscope field selection, 216 
again, could play a role in this. Interestingly, tumour differentiation score was perfect for the 217 
intra-observer study. This, along with strong to almost perfect agreement on other criteria, 218 
indicated consistency in single-pathologist evaluation in canine STS. 219 
To minimise the undesired effect of inter-observer variability in the histological assessment 220 
of canine STS, recommendations have been made to minimise inconsistency among 221 
pathologists.1 These recommendations included assessment of areas that are well-fixed and 222 
not overly complicated by inflammation and/or haemorrhage; mitotic index should be 223 
assessed within the most cellular part of the tumour and the area with the highest mitotic 224 
activity; differentiation should represent the histologic types and the true differentiation of the 225 
tumour; uncertainty regarding histogenesis has no bearing on degree of differentiation.1 In 226 
addition to following these recommendations, the integration of more objective assessments 227 
may also be beneficial. The incorporation of immunohistochemical assessment, especially 228 
the non-morphological, proliferative markers such as Ki-67 counts and AgNOR assay, may 229 
improve the diagnostic specificity, and hence accuracy of prognostic advice on STS in 230 
dogs.17,20,21 Further development in molecular genetics of canine STS and the use of 231 
automated mitosis detection may also provide consistent and accurate diagnosis. 6,22 232 
One of the limitations of this study is the lack of comparison of the results to the ‘real’ results 233 
(such as the ‘real’ tumour grading or the ‘real’ mitotic rate). The intra-observer study showed 234 
strong to prefect agreement in all parameters assessed, indicating a strong consistency or 235 
precision. The inter-observer study showed moderate agreement, hence precision, in most 236 
parameters assessed. However, precision differs from accuracy; accuracy refers to the 237 
proximity of a measured value to the actual/’real’ value whereas the term precision refers to 238 
the repeatability of a measurement.23 As a result, a single-pathologist’s histological 239 
assessment of canine STS can be precise and accurate at the same time or it can be 240 
precise but inaccurate. Similarly, the moderate agreement and precision among pathologists 241 
did not necessary equate to moderate accuracy. The clinical application of this limitation is 242 
unknown as there is currently no test that can provide perfect accuracy in the histological 243 
assessment of canine STS. 244 
Another limitation of the study is the small numbers of pathologists recruited. A previous 245 
study assessing reproducibility of histological grading in human STS had 15 pathologists as 246 
well as an additional separate panel involved in the study.8 Despite the smaller number of 247 
pathologists involved in our study, the inter-observer agreement on histological grading was 248 
comparable (κ values of 0.49 and 0.44) to that of the human study.8 249 
Conclusion 250 
Histological assessment of canine STS by an individual pathologist had high reproducibility. 251 
However, the agreement among pathologists for the diagnosis and grading of canine STS 252 
was moderate. Future studies are required to investigate further assessment criteria to 253 
improve the specificity of canine STS diagnosis and grading. 254 
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Table 1: Histological criteria assessed and scores assigned1 257 
Differentiation score 
1 Sarcomas most closely resembling normal adult mesenchymal 
tissue, by type (eg, well differentiated perivascular wall or 
peripheral nerve sheath tumours, well-differentiated 
fibrosarcomas, or well-differentiated liposarcomas) 
2 Sarcomas for which histologic type can be determined, although 
differentiation is poor (eg, poorly differentiated liposarcoma, 
fibrosarcoma, poorly differentiated perivascular wall tumour or 
peripheral nerve sheath tumour) 
3 Undifferentiated sarcomas, sarcomas of unknown type 
Mitosis score: mitoses per 10 high-power fields (400x) 
1 0 – 9 
2 10 – 19 
3 > 19 
Tumour necrosis score 
0 No necrosis 
1 ≤ 50% necrosis 
2 > 50% necrosis 
 258 
  259 
Table 2: Grade assigned1 260 
Grade Cumulative scores of the three categories from Table 1 
I ≤ 3 
II 4 - 5 
III ≥ 6 
 261 
Table 3: Interpretation of intraclass correlation and Kappa values 262 
ICC and Kappa values Levels of agreement 
≤ 0.2 Poor 
0.21 to 0.40 Fair 
0.41 to 0.60 Moderate 
0.61 to 0.80 Strong 
> 0.80 Almost perfect 
 263 
  264 
Table 4: Intraclass correlation values (intra-observer agreement) 265 
Parameters ICC Agreement 
Necrosis score 0.79 Strong 
Mitotic score 0.78 Stro 
ng 
Differentiation score 1.00 Perfect 
Total score 0.91 Almost perfect 
Grade of STS 0.91 Almost perfect 
 266 
Table 5: Kappa values (inter-observer agreement) 267 
Parameters Kappa Agreement 
Necrosis score 0.46 Moderate 
Mitotic score 0.57 Moderate 
Differentiation score 0.11 Poor 
Total score 0.20 Fair 
Grade of STS 0.43 Moderate 
STS, yes or no? 0.60 Moderate 
 268 
  269 
Figure 1: Two pathologists considered this as a soft tissue sarcoma (STS); for the third 270 
pathologist (in no particular order), the differential diagnosis for this were histiocytic sarcoma 271 
or haemangiosarcoma. Haematoxylin and eosin, objective lens ×20. 272 
 273 
  274 
Figure 2: Two pathologists graded this as a grade III soft tissue sarcoma (STS), 1 275 
pathologist graded this as a grade II STS. Haematoxylin and eosin, objective lens ×20. 276 
  277 
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